NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment - Scoping

Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis ID6487

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes, the following potential equality issues were raised at scoping consultation stage:

- the population considered in the scope is adults GPB 1% cream could have the greatest impact when used by adolescents
- hyperhidrosis is often self-managed there are significant out of pocket costs which may lead to inequality based on income and affordability
- there are challenges regarding geographic availability for some current therapies – for example botox, which is available in some areas but not others
- 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
 - Regarding the issue around adolescents, the appraisal committee will be bound by indication wording in the marketing authorisation
 - Inequality based on income or geographic availability are both important considerations, but not related to the protected characteristics in the Equalities Act 2010. The economic evaluation will consider the costs to the NHS and personal social services with

glycopyrronium bromide cream compared with treatments used in the NHS. It is anticipated that the any variation in access to treatments for hyperhidrosis and patient perspectives on this will be considered by the appraisal committee during the evaluation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

Approved by Associate Director: Emily Crowe...

Date: 26/02/2025